Legal & General Group Plc Makes New Investment in Omeros Corporation $OMER

Posted by Stanley Muller on Sep 9th, 2026

Legal & General Group Plc bought a new position in Omeros Corporation (NASDAQ:OMER – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 44,686 shares of the biopharmaceutical company’s stock, valued at approximately $425,000. Legal & General Group Plc owned approximately 0.06% of Omeros at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Omeros during the second quarter valued at $57,484,000. Vanguard Group Inc. raised its position in Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after buying an additional 666,357 shares during the last quarter. Geode Capital Management LLC lifted its stake in Omeros by 6.3% during the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock valued at $28,026,000 after acquiring an additional 95,979 shares during the period. State Street Corp lifted its stake in Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock valued at $27,025,000 after acquiring an additional 333,798 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in shares of Omeros by 39.3% during the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock valued at $3,827,000 after acquiring an additional 263,095 shares during the last quarter. 48.79% of the stock is owned by institutional investors.

Insider Buying and Selling at Omeros

In other Omeros news, CAO David Borges sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the sale, the chief accounting officer directly owned 5,906 shares of the company’s stock, valued at approximately $111,918.70. This represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Cable sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total transaction of $276,750.00. Following the sale, the director directly owned 35,067 shares of the company’s stock, valued at approximately $646,986.15. This represents a 29.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 95,906 shares of company stock valued at $1,780,205. 10.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Weiss Ratings upgraded shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 3rd. HC Wainwright restated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Finally, Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Get Our Latest Report on Omeros

Omeros Stock Performance

Shares of NASDAQ:OMER opened at $19.12 on Wednesday. The stock’s 50-day simple moving average is $13.89 and its two-hundred day simple moving average is $12.39. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of 14.94 and a beta of 2.60. Omeros Corporation has a 52-week low of $3.94 and a 52-week high of $19.65.

Omeros (NASDAQ:OMER – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. As a group, equities analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Omeros Profile

(Free Report)

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.